A. Shand

S. Ghosh, A. Shand, J. Bode, 2002, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Role of infliximab in ulcerative colitis: further questions.

C. Lees, J. Satsangi, I. Arnott, 2006, Inflammatory bowel diseases.

Use of methotrexate in refractory Crohn's disease: The Edinburgh experience

J. Satsangi, I. Arnott, A. Shand, 2008, Inflammatory bowel diseases.

PTH-128 The Frax Algorithm is of Limited Utility in Predicting Osteoporosis in Coeliac Disease

J. Satsangi, S. Ralston, N. Kennedy, 2013, Gut.

Profound diarrhoea and weight loss in an immunocompromised patient

I. Arnott, A. Shand, S. Din, 2021, BMJ Case Reports.

Erythromycin for the treatment of chronic intestinal pseudo‐obstruction: description of six cases with a positive response

M. Kamm, A. Emmanuel, M. A. Kamm, 2004, Alimentary pharmacology & therapeutics.

A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis

C. Lees, J. Satsangi, C. Mowat, 2007, Alimentary pharmacology & therapeutics.

Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis

H. Drummond, J. Satsangi, M. Dunlop, 2009, The American Journal of Gastroenterology.

Endoscopic fibrin sealant injection: a novel method of closing a refractory gastrocutaneous fistula.

A. Shand, M. Papachrysostomou, S. Ghosh, 1997, Gastrointestinal endoscopy.

Lack of association between cervical dysplasia and IBD: A large case–control study

C. Lees, J. Satsangi, J. Critchley, 2009, Inflammatory bowel diseases.

A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta‐analysis

C. Lees, J. Satsangi, N. Kennedy, 2013, Alimentary pharmacology & therapeutics.

Explorer Characterisation of osteoprotegerin autoantibodies in coeliac disease

J. Satsangi, S. Ralston, N. Kennedy, 2017 .

Characterisation of Osteoprotegerin Autoantibodies in Coeliac Disease

J. Satsangi, S. Ralston, N. Kennedy, 2015, Calcified Tissue International.

Potential therapeutic role for cytokine or adhesion molecule manipulation in Crohn's disease: in the shadow of infliximab?

A. Forbes, A. Shand, 2002, International Journal of Colorectal Disease.

P459 Vedolizumab for the treatment of chronic pouchitis: the Edinburgh experience

C. Lees, I. Arnott, A. Shand, 2019, Journal of Crohn's and Colitis.

1043 The Efficacy of Corticosteroid Therapy: Analysis of 10-Year Inflammatory Bowel Disease Inception Cohort (1998-2007)

H. Drummond, J. Satsangi, I. Arnott, 2008 .

Expandable metallic stents for palliation of malignant pyloric and duodenal obstruction

A. Shand, D. C. Grieve, J. Brush, 2002, The British journal of surgery.

PTU-002 Achieving biochemical remission in crohn’s disease with adalimumab therapy utilsing therapeutic drug monitoring

C. Lees, I. Arnott, C. Noble, 2018, IBD.

Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission.

C. Lees, I. Arnott, G. Ho, 2018, Inflammatory bowel diseases.

564 Elevated Faecal Calprotectin Predicts Disease Progression in Crohn's Disease

Thomas J. Smith, H. Drummond, C. Lees, 2013 .

Anti-TNF-alpha therapy for orofacial granulomatosis: proceed with caution.

J. Satsangi, D. Gaya, J. Fennell, 2006, Gut.

Gastric fundic gland polyps in south‐east Scotland: Absence of adenomatous polyposis coli gene mutations and a strikingly low prevalence of Helicobacter pylori infection

Subrata Ghosh, J. Coia, A. Shand, 2002, Journal of gastroenterology and hepatology.

P416 Real world data on the effectiveness and safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis: the Edinburgh experience.

C. Lees, J. Satsangi, I. Arnott, 2017, Journal of Crohn's & colitis.

Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC)

R. Prescott, C. Lees, J. Satsangi, 2023, Cellular and molecular gastroenterology and hepatology.

PTU-122 A trial with mercaptopurine following azathioprine intolerance is a safe treatment strategy for the majority of patients with IBD

C. Lees, J. Satsangi, N. Kennedy, 2012, Gut.

Palliation of a malignant gastrocolic fistula by endoscopic human fibrin sealant injection.

A. Parker, A. Shand, D. Welsh, 1997, European journal of gastroenterology & hepatology.

The prevalence and transcriptional activity of the mucosal microbiota of ulcerative colitis patients

S. Heath, H. Drummond, C. Lees, 2018, Scientific Reports.

Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4.

Subrata Ghosh, I. Arnott, A. Shand, 2000 .

Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4

Subrata Ghosh, I. Arnott, A. Shand, 2000, American Journal of Gastroenterology.

Anti-TNF-α therapy for renal amyloid as a complication of Crohn's disease.

V. Save, C. Bellamy, J. Plevris, 2014, QJM : monthly journal of the Association of Physicians.

Lack of association between cervical dysplasia and IBD: A large case–control study

C. Lees, J. Satsangi, J. Critchley, 2009, Inflammatory bowel diseases.

GASTRIC CARCINOMA: EXPERIMENTAL AND CLINICAL Gastric fundic gland polyps in south-east Scotland: Absence of adenomatous polyposis coli gene mutations and a strikingly low prevalence of Helicobacter pylori infection

Subrata Ghosh, J. Coia, A. Shand, 2002 .

Anti-TNF-α therapy for orofacial granulomatosis: proceed with caution

K. Chu, D. Gaya, J. Fennell, 2006, Gut.